other material
confidence high
sentiment positive
materiality 0.65
uniQure reports AMT-260 Phase I/IIa data: 3/6 patients saw 79-100% seizure reduction; no SAEs
uniQure N.V.
- Three of six patients in low-dose cohort achieved 79% to 100% decline in disabling seizures (months 4-6).
- Remaining three patients had variable changes: -33% to +36% from baseline.
- No serious adverse events related to AMT-260 or surgery; all AEs mild/moderate, headache most common (N=2).
- Enrollment ongoing for second, higher-dose cohort (3x10¹² gc/mL), expected completion mid-2026; updated results H1 2027.